Pediatric Drug-Sensitive TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

| Medicines | WHO Guidelines (DS-TB '17) | WHO Rapid Communication (DS-TB '21) | EMLcsubmitted | EMLc (2019) | WHO PQ EOI (2021) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (Nov 2020) | Global Fund ERP approved | GDF Catalog |
|-------------------------------------|-------------------------------|---|---------------|-------------|-------------------|--------------------------------|---------------|---|-----------------------------------|-----------------------------|-------------|
| Ethambutol 25mg/mL oral liquid | | | | | | | | | | | |
| Ethambutol 50mg dispersible tablet | | | | | | | | | | | |
| Ethambutol 100mg dispersible tablet | | | | | | | | | | | |
| Ethambutol 100mg tablet | | | | | | | | | | | |
| Isoniazid 50mg dispersible tablet | | | | | | | | | | | |
| Isoniazid 50mg tablet scored | | | | | | | | | | | |
| Isoniazid 50mg/5mL oral liquid | | | | | | | | | | | |
| Isoniazid 100mg dispersible tablet | | | | | | | | | | | |

DS-TB: Drug-Sensitive TB

EML: Essential Medicines List

 $\hbox{\bf EOI:} \ {\sf Expression} \ {\sf of} \ {\sf Interest}$

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status
Yes
No

N/A

Ineligible for inclusion



Pediatric Drug-Sensitive TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

| Medicines | WHO Guidelines (DS-TB '17) | WHO Rapid Communication (DS-TB '21) | EMLcsubmitted | EMLc (2019) | WHO PQ EOI (2021) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (Nov 2020) | Global Fund ERP approved | GDF Catalog |
|---------------------------------------|-------------------------------|---|---------------|-------------|-------------------|--------------------------------|---------------|---|-----------------------------------|-----------------------------|-------------|
| Isoniazid 100mg tablet | | | | | | | | | | | |
| Isoniazid 300mg tablet/capsule | | | | | | | | | | | |
| Moxifloxacin 100mg dispersible tablet | | | | | | | | | | | |
| Moxifloxacin 400mg tablet/capsule | | | | | | | | | | | |
| Pyrazinamide 30mg/mL oral liquid | | | | | | | | | | | |
| Pyrazinamide 150mg dispersible tablet | | | | | | | | | | | |
| Pyrazinamide 150mg tablet scored | | | | | | | | | | | |
| Rifampicin 20mg/mL oral liquid | | | | | | | | | | | |

DS-TB: Drug-Sensitive TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status
Yes
No

N/A

Ineligible for inclusion



Pediatric Drug-Sensitive TB Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

| Medicines | WHO Guidelines (DS-TB'17) | WHO Rapid Communication (DS-TB '21) | EMLcsubmitted | EMLc (2019) | WHO PQ EOI (2021) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (Nov 2020) | Global Fund ERP approved | GDF Catalog | Status Yes No Ineligible for inclusion N/A |
|---|------------------------------|---|---------------|-------------|-------------------|--------------------------------|---------------|---|-----------------------------------|-----------------------------|-------------|--|
| Rifampicin/Isoniazid 75/50 dispersible tablet | | | | | | | | | | | | |
| Rifampicin/Isoniazid/ Pyrazinamide 75/50/150mg dispersible tablet | | | | | | | | | | | | |
| Rifapentine 150mg dispersible tablet | | | | | | | | | | | | |
| Rifapentine 150mg tablet | | | | | | | | | | | | |
| Rifapentine 300mg | | | | | | | | | | | | |
| Rifapentine/Isoniazid 300mg/300mg tablet | | | | | | | | | | | | |

DS-TB: Drug-Sensitive TB **EML:** Essential Medicines List **EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







